Byron Hann

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants
    Byron Hann
    University of California San Francisco Cancer Research Institute, San Francisco, California 94143 0875, USA
    J Virol 77:11588-95. 2003
  2. ncbi request reprint Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy
    Katherine A Rauen
    Department of Pediatrics, University of California, San Francisco, California 94115, USA
    Cancer Res 62:3812-8. 2002
  3. pmc Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Mark M Moasser
    Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
    J Magn Reson Imaging 26:1618-25. 2007
  4. pmc Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers
    Ching Hang Wong
    Department of Medicine, University of California, San Francisco, San Francisco, California 94143 0875, USA
    Clin Cancer Res 15:2311-22. 2009
  5. pmc Resiliency and vulnerability in the HER2-HER3 tumorigenic driver
    Dhara N Amin
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    Sci Transl Med 2:16ra7. 2010
  6. ncbi request reprint Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription
    Corina Marx
    Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, CA 94945, USA
    Assay Drug Dev Technol 4:273-84. 2006
  7. pmc Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
    Natalia V Sergina
    Department of Medicine, University of California, San Francisco 94143, USA
    Nature 445:437-41. 2007
  8. ncbi request reprint Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer
    Corina Marx
    Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA
    Mol Pharmacol 71:1525-34. 2007

Collaborators

Detail Information

Publications8

  1. pmc Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants
    Byron Hann
    University of California San Francisco Cancer Research Institute, San Francisco, California 94143 0875, USA
    J Virol 77:11588-95. 2003
    ..These observations indicate that the nature of the p53 mutation affects ONYX-015 replication, help reconcile disparate published findings, and may provide criteria by which to direct clinical application of ONYX-015...
  2. ncbi request reprint Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy
    Katherine A Rauen
    Department of Pediatrics, University of California, San Francisco, California 94115, USA
    Cancer Res 62:3812-8. 2002
    ..Adenovirus therapy may, therefore, provide an alternate modality in the treatment of prostate cancer and may be especially efficacious in the treatment of metastatic disease...
  3. pmc Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Mark M Moasser
    Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
    J Magn Reson Imaging 26:1618-25. 2007
    ..Poor tumor vascular function limits the delivery and efficacy of cancer chemotherapeutics and HER family tyrosine kinases mediate tumor-endothelial signaling in both of these compartments...
  4. pmc Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers
    Ching Hang Wong
    Department of Medicine, University of California, San Francisco, San Francisco, California 94143 0875, USA
    Clin Cancer Res 15:2311-22. 2009
    ....
  5. pmc Resiliency and vulnerability in the HER2-HER3 tumorigenic driver
    Dhara N Amin
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    Sci Transl Med 2:16ra7. 2010
    ..This strategy for inactivation of HER2-HER3 tumorigenic activity is proposed for clinical testing...
  6. ncbi request reprint Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription
    Corina Marx
    Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, CA 94945, USA
    Assay Drug Dev Technol 4:273-84. 2006
    ....
  7. pmc Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
    Natalia V Sergina
    Department of Medicine, University of California, San Francisco 94143, USA
    Nature 445:437-41. 2007
    ..The biologic marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation...
  8. ncbi request reprint Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer
    Corina Marx
    Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA
    Mol Pharmacol 71:1525-34. 2007
    ....